CytoDynCYDY -0.48%28 ROE % is 0.00% as of Feb. 2026. GuruFocus rates CYDY with a GF Score™ of 28/100. The stock has 1 warning sign investors should review. Among 1,252 Biotechnology companies, CytoDyn ranks worse than 79872.12% on this metric.
ROE % is calculated as Net Income divided by its average Total Stockholders Equity over a certain period of time. CytoDyn's annualized net income for the quarter that ended in Feb. 2026 was $-18.76 Mil. CytoDyn's average Total Stockholders Equity over the quarter that ended in Feb. 2026 was $-112.02 Mil. Therefore, CytoDyn's annualized ROE % for the quarter that ended in Feb. 2026 was N/A%.
The historical rank and industry rank for CytoDyn's ROE % or its related term are showing as below:
CYDY's ROE % is not ranked *
in the Biotechnology industry.
Industry Median: -38.145 * Ranked among companies with meaningful ROE % only.
CytoDyn (OTCPK:CYDY) ROE % Explanation
ROE % measures the rate of return on the ownership interest (shareholder's equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' equity (also known as net assets or assets minus liabilities). ROE % shows how well a company uses investment funds to generate earnings growth. ROE %s between 15% and 20% are considered desirable.
The factors that affect a company's ROE % can be illustrated with the three-step DuPont Analysis:
Note:
The net income data used here is four times the quarterly (Feb. 2026) net income data. The Revenue data used here is four times the quarterly (Feb. 2026) revenue data. The same rule applies to Pre-Tax Income and Operating Income.
* In the five-step DuPont Analysis, Operating Income is only available for non-financial companies. Thus, for Insurance companies, we use EBIT as a substitution of Operating Income. For Banks, both Operating Income and EBIT is unavailable. Thus we combined Interest Burden and Operating Margin % into Pretax Margin %, and the DuPont Analysis is divided into four components instead.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Be Aware
Net Income is used.
Because a company can increase its ROE % by having more financial leverage, it is important to watch the equity multiplier when investing in high ROE % companies. Like ROA %, ROE % is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.
Asset light businesses require very few assets to generate very high earnings. Their ROE %s can be extremely high.
CytoDyn ROE % Related Terms
CytoDyn ROE % Historical Data
* Premium members only.
The historical data trend for CytoDyn's ROE % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, CytoDyn's ROE %, along with its competitors' market caps and ROE % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
CytoDyn ROE % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, CytoDyn's ROE % distribution charts can be found below:
* The bar in red indicates where CytoDyn's ROE % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual ROE %, the net income of the last fiscal year and the average total shareholder equity over the fiscal year are used. In calculating the quarterly data,
the net income data used here is four times the quarterly (Feb. 2026) net income data.
ROE % is displayed in the 30-year financial page.
* Note that if the average Total Stockholders Equity is zero or negative, then ROE % would be considered meaningless and hence not be calculated.
CytoDyn (CYDY) has a ROE % of 0.00% as of Feb. 2026. Return on equity is the ratio of current-period net income to average two-period total equity. View historical data on CytoDyn and its competitors. According to the industry distribution chart, CytoDyn ranks #999999 out of 1252 companies in the Biotechnology industry.
Is CytoDyn's ROE % too high?
CytoDyn's current ROE % is 0.00%. Based on the distribution chart, CytoDyn ranks #999999 out of 1252 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, CytoDyn has a GF Score™ of 28/100, reflecting its overall financial health beyond just this single metric.
How does CytoDyn's ROE % compare to ZURA and XFOR?
According to the Biotechnology industry distribution chart, CytoDyn ranks #999999 out of 1252 companies for ROE %. This places CytoDyn in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROE % for a Biotechnology company?
A good ROE % depends on the Biotechnology industry context. However, ROE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROE % mean?
A high ROE % can signal that a stock is expensive relative to its fundamentals. Return on equity is the ratio of current-period net income to average two-period total equity. View historical data on CytoDyn and its competitors. CytoDyn's current ROE % is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is CytoDyn stock overvalued right now?
CytoDyn (CYDY) has a current ROE % of 0.00%. The current ROE % is 0.00%. CytoDyn's overall GF Score™ is 28/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROE % calculated?
ROE % is calculated from a company's financial statements. For CytoDyn (CYDY), the current ROE % is 0.00% as of Feb. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
CytoDyn Inc is a USA-based clinical-stage biotechnology company that focuses on the clinical development and potential commercialization of humanized monoclonal antibodies to treat Human Immunodeficiency Virus (HIV) infection. The product candidate is PRO 140, which is a class of HIV therapy called entry inhibitors that block HIV from entering into and infecting certain cells. The company emphasizes exploring opportunities for clinical applications for PRO 140 involving the CCR5 (C-C chemokine receptor type 5) receptor, other than HIV-related treatments, such as inflammatory conditions, autoimmune diseases, and cancer.
28GF Score
Get the complete analysis for CYDY
ROE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CYDY has been successfully added to your 
